GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarti Drugs Ltd (BOM:524348) » Definitions » Capex-to-Revenue

Aarti Drugs (BOM:524348) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Aarti Drugs Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Aarti Drugs's Capital Expenditure for the three months ended in Mar. 2024 was ₹0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was ₹6,199.90 Mil.

Hence, Aarti Drugs's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.00.


Aarti Drugs Capex-to-Revenue Historical Data

The historical data trend for Aarti Drugs's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarti Drugs Capex-to-Revenue Chart

Aarti Drugs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.04 0.06 0.06 0.09

Aarti Drugs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aarti Drugs's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Drugs's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aarti Drugs's Capex-to-Revenue falls into.



Aarti Drugs Capex-to-Revenue Calculation

Aarti Drugs's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2263.3) / 25285.8
=0.09

Aarti Drugs's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 6199.9
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aarti Drugs  (BOM:524348) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Aarti Drugs Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aarti Drugs's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aarti Drugs (BOM:524348) Business Description

Traded in Other Exchanges
Address
Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400 022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs) in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm generates the majority of its revenue from India.

Aarti Drugs (BOM:524348) Headlines

No Headlines